30 November 2022,Raffles PharmaTech has successfully obtained a Drug Manufacturing License issued by the Guangdong NMPA, certificate No.粤20220025,classification code Dh.
The recognition by the regulatory authority marks an important development milestone for the company.
Raffles PharmaTech was created in 2011 by scientists from leading global companies driven to build a platform for world-class small molecule development and cGMP manufacturing.
The company with head-quarters in Guangdong, China, currently employs more than 450 staff supporting Innovative pharmaceutical development across the globe.
With Chemistry at the core of the organization the company engages in route discovery,process development, optimization,scale-up and cGMP manufacture of Key materials, Intermediates, Active Pharmaceutical Ingredients.
Route discovery, process development, optimization, scale-up and cGMP manufacture.KRMs,RSMs, Intermediates, APIs.
Support Platforms Overview
Early Study Lab Scale Synthesis
Early Phase Process Development
Clinical Trial APIs & Late Phase RSMs
IND，NDA to Commercial Supply Analytical Open Lab
Chemical Analytical Service Lab Analytical Research Development to QC cGMP QC/QA System